Somford, D. M. and Daneshmand, S. and Grivas, P. and Sridhar, S. and Gupta, S. and Bellmunt, J. and Sonpavde, G. and Fleming, M. T. and Lerner, S. P. and Loriot, Y. and Li, A. and Takkele, H. and Andresen, C. and Rearden, J. and Shepherd, S. Peacock and Schnabel, M. J. and Pal, S. K. (2020) PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. In: ESMO Virtual Congress, SEP 19-OCT 18, 2020, ELECTR NETWORK.
Full text not available from this repository.
Official URL: https://www.sciencedirect.com/journal/annals-of-on...
| Item Type: | Conference or Workshop Item (UNSPECIFIED) |
|---|---|
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 16 Apr 2021 05:00 |
| Last Modified: | 16 Apr 2021 05:00 |
| URI: | https://pred.uni-regensburg.de/id/eprint/43895 |
Actions (login required)
 |
View Item |
